India, Jan. 15 -- Sanofi Winthrop Industrie announced that China's National Medical Products Administration (NMPA) has granted approval for two innovative Sanofi-licensed medicines. Myqorzo (aficamten) has been authorized for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), while Redemplo (plozasiran) has been approved to lower triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) who are managed through dietary control.
Myqorzo is a selective, small-molecule cardiac myosin inhibitor to improve functional capacity and relieve symptoms in patients with oHCM, in which the myocardium, the heart muscle, becomes abnormally thick. It is the most common monogenic inherited cardiovascular disorder.
Re...